G1 Therapeutics Inc. (GTHX)
7.16
0.01 (0.14%)
At close: Sep 17, 2024, 7:56 PM
0.14% (1D)
| Bid | 7.14 |
| Market Cap | 377.75M |
| Revenue (ttm) | 58.2M |
| Net Income (ttm) | -44.77M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -8.325581395348838 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 7.16 |
| Volume | 1,097,310 |
| Avg. Volume (20D) | 2,229,441 |
| Open | 7.15 |
| Previous Close | 7.15 |
| Day's Range | 7.14 - 7.16 |
| 52-Week Range | 1.08 - 7.19 |
| Beta | 1.68 |
About GTHX
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer...
Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2017
Employees 100
Stock Exchange NASDAQ
Ticker Symbol GTHX
Website https://www.g1therapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GTHX stock is "Hold." The 12-month stock price forecast is $3, which is a decrease of -58.10% from the latest price.
Stock Forecasts8 months ago
+66.12%
G1 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
10 months ago
-10.48%
G1 Therapeutics shares are trading lower after the company's PRESERVE 2 Phase 3 trial of Trilaciclib did not achieve statistical significance in the primary endpoint of overall survival.